Another study demonstrated the predictive role of IL-8 in 1445 patients with urothelial carcinoma (UC) and RCC treated with atezolizumab in clinical trials (IMvigor210, IMvigor211, and IMmotion 150) [71]. Here, CXCL8 is linked to renal cell carcinoma.